1. Home
  2. SMTI

as of 11-13-2026 10:16am EST

$32.54
+$0.03
+0.11%
Stocks Health Care Medical/Dental Instruments Nasdaq

Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.

Founded: 1982 Country:
United States
United States
Employees: N/A City: FORT WORTH
Market Cap: 322.2M IPO Year: 2008
Target Price: $35.00 AVG Volume (30 days): 95.7K
Analyst Decision: Hold Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.05 EPS Growth: -282.46
52 Week Low/High: $16.05 - $35.52 Next Earning Date: 11-12-2026
Revenue: $15,586,976 Revenue Growth: 32.47%
Revenue Growth (this year): 13.07% Revenue Growth (next year): 14.23%
P/E Ratio: -650.10 Index:
Free Cash Flow: 2.2M FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 12, 2026 · 100% conf.

AI Prediction SELL

1D

-3.58%

$31.34

Act: +0.08%

5D

-4.91%

$30.91

20D

+1.81%

$33.09

Price: $32.51 Prob +5D: 0% AUC: 1.000
0001493152-26-051394

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Sanara MedTech Inc. Reports Third Quarter 2026 Financial Results (Unaudited)

FORT

WORTH, TX, November 12, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Summary(1)

●Net revenue increased 8% to $28.4 million, compared to $26.3 million in the third quarter of 2025.

●Gross profit of $26.3 million, or 93% of net revenue, compared to gross profit of $24.5 million, or 93% of net revenue, in the third quarter of 2025.

●Operating income of $0.7 million, compared to operating income of $2.9 million in the third quarter of 2025. Third quarter operating income included approximately $3.0 million in legal and advisory services associated with corporate strategic initiatives and the pending merger with MiMedx Group, Inc. (“MIMEDX” and the proposed transaction, the “Merger”).

●Net loss from continuing operations of $1.3 million, or a loss of $0.15 per diluted share, compared to net income from continuing operations of $0.8 million, or $0.09 per diluted share, in the third quarter of 2025.

●Adjusted EBITDA(2) of $5.6 million, compared to $4.9 million in the third quarter of 2025.

First Nine Months of 2026 Financial Summary(1)

●Net revenue increased 12% to $84.4 million, compared to $75.6 million in the first nine months of 2025.

●Gross profit of $78.4 million, or 93% of net revenue, compared to gross profit of $69.9 million, or 93% of net revenue, in the first nine months of 2025.

●Operating income of $5.2 million, compared to operating income of $6.3 million in the first nine months of 2025. Operating income for the first nine months included approximately $4.1 million in legal and advisory services associated with corporate strategic initiatives and the pending Merger.

●Net loss from continuing operations of $1.3 million, or a loss of $0.15 per diluted share, compared to net income from continuing operations of $0.7 million, or $0.08 per diluted share, in the first nine months of 2025.

●Adjusted EBITDA(2) of $14.9 million, compared to $12.3 million in the first nine months of 2025.

●Cash and cash equivalents of $16.8 million and $46.7 million of long-term debt at September 30, 2026, compared to $16.6 million of cash and cash equivalents and $46.0 million of long-term debt at December 31, 2025.

(1)As a result of the Company’s strategic realignment, the balance sheets and statements of operations of Tissue Health Plus (“THP”), which were previously reported as the THP segment, have been classified as discontinued operations and excluded from continuing operations for the three and nine months ended September 30, 2026 and 2025.

(2)Adjusted EBITDA is a non-GAAP financial measure. See the discussion and the reconciliation at the end of this release for additional information.

Management Comments

Seth Yon, President and Chief Executive Officer of Sanara, commented, “Our team delivered another quarter of strong execution with net revenue of $28.4 million, representing 8% growth year-over-year, gross margin of 93% and Adjusted EBITDA of $5.6 million. CellerateRX Surgical and BIASURGE continue to be strong drivers of our revenue growth.

“In July, we announced our entry into a transformational agreement in which Sanara is expected to be acquired by MIMEDX. We were pleased to receive shareholder approval for the pending combination in September, and we continue to work through the regulatory and review process. We believe this is a significant next step for Sanara’s growth and we remain excited about the opportunity this transaction represents for our customers, employees and shareholders,” Mr. Yon concluded.

Third Quarter and Year-to-Date 2026 Revenue

The following table summarizes revenue streams from product sales for the periods presented:

Three Months Ended

September 30,

Nine Months Ended September 30,

2026 2025 2026 2025

Soft tissue repair products $25,662,232 $23,424,126 $75,847,769 $66,618,023

Bone fusion products 2,767,926 2,909,693 8,517,680 8,954,144

Total Net Revenue $28,430,158 $26,333,819 $84,365,449 $75,572,167

Third Quarter of 2026 Financial Results(1)

Net revenue for the third quarter of 2026 was $28.4 million, compared to $26.3 million for the third quarter of 2025, an increase of $2.1 million, or 8%, year-over-year. Higher net revenue for the third quarter of 2026 was driven by an increase of $2.2 million, or 10%, in sales of soft tissue repair products, including CellerateRX® Surgical Powder (“CellerateRX Surgical”) and BIASURGE® Advanced Surgical Solution (“BIASURGE”), offset by a slight decrease of $0.1 million, or 5%, in sales of bone fusion products. The increase

2026
Q2

Q2 2026 Earnings

8-K BUY

Aug 11, 2026 · 85% conf.

AI Prediction BUY

1D

+6.48%

$36.61

Act: -0.15%

5D

+8.06%

$37.15

20D

+9.00%

$37.48

Price: $34.38 Prob +5D: 92% AUC: 1.000
0001493152-26-037131

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K BUY

May 11, 2026 · 100% conf.

AI Prediction BUY

1D

+6.37%

$19.17

Act: +13.43%

5D

+7.44%

$19.36

Act: +21.48%

20D

+8.11%

$19.48

Act: +26.08%

Price: $18.02 Prob +5D: 100% AUC: 1.000
0001493152-26-022291

EX-99.1

2 ex99-1.htm

EX-99.1

Exhibit 99.1

Sanara MedTech Inc. Reports First Quarter 2026 Financial Results (Unaudited)

Net Revenue Growth of 19% and Net Profitability from Continuing Operations of $0.04 Per Fully Diluted Share for the Quarter

FORT

WORTH, TX, May 11, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported its financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Summary(1)

●Net revenue increased 19% to $27.8 million, compared to $23.4 million in the first quarter of 2025.

●Gross profit of $25.9 million, or 93% of net revenue, compared to gross profit of $21.6 million, or 92% of net revenue, in the first quarter of 2025.

●Operating income of $2.6 million, compared to operating income of $0.8 million in the first quarter of 2025.

●Net income from continuing operations of $0.4 million, or $0.04 per diluted share, compared to net loss from continuing operations of $0.6 million, or $0.07 per diluted share, in the first quarter of 2025.

●Adjusted EBITDA(2) of $4.3 million, compared to $2.7 million in the first quarter of 2025.

●Cash of $13.6 million and $46.2 million of long-term debt at March 31, 2026, compared to $16.6 million of cash and $46.0 million of long-term debt at December 31, 2025.

(1) As a result of the Company’s strategic realignment, the operations of Tissue Health Plus (“THP”), which were previously reported as the THP segment, have been classified as discontinued operations in Sanara’s financial statements for the three months ended March 31, 2026 and 2025.

(2) Adjusted EBITDA is a non-GAAP financial measure. See the discussion and the reconciliation at the end of this release for additional information.

Management Comments

Seth Yon, President and Chief Executive Officer of Sanara, commented, “The first quarter of 2026 is the first full quarter in which the Company was entirely focused on the surgical market, and the results reflected strong execution. We delivered net revenue growth of 19% and gross margin improvement, and achieved GAAP net profitability, a reflection of the strength of our sharpened focus and enhanced financial model. We’re particularly encouraged by these results given that the first quarter is historically our slowest sales period of the year and was also impacted by a three-day shipping interruption in January due to a weather-related shut down.

“During the end of 2025 and continuing into 2026, we began strengthening our sales team in an effort to support enhanced net revenue growth and our heightened focus on the surgical setting, expanding the sales team to reach a total of 43 reps,” Mr. Yon stated. “Additionally, we experienced meaningful growth in our surgeon users in the first quarter of 2026 as compared to the first quarter of 2025, and, as of quarter end, our products were contracted or approved to be sold in over 4,000 hospitals and ambulatory surgery centers throughout the United States, our products were sold in over 1,400 facilities throughout the United States, and we had agreements with more than 450 distributors.

“Looking ahead, we believe we are well positioned with our strengthened sales team and refined, pure play focus on the surgical operating setting to drive enhanced results. From a capital allocation perspective, this means tightening our scope and strategically investing in R&D to grow our pipeline and introduce new products to the market. With our visibility today, we remain confident in our full-year guidance of 13% to 17% net revenue growth,” Mr. Yon concluded.

First Quarter of 2026 Revenue

The following table summarizes revenue streams from product sales for the three months ended March 31, 2026 and 2025:

Three Months Ended

March 31,

2026 2025

Soft tissue repair products $24,942,945 $20,532,440

Bone fusion products 2,855,589 2,901,656

Total Net Revenue $27,798,534 $23,434,096

First Quarter of 2026 Financial Results(1)

Net revenue for the first quarter of 2026 was $27.8 million, compared to $23.4 million for the first quarter of 2025, an increase of $4.4 million, or 19%, year-over-year. The increase in net revenue was driven by an increase of $4.4 million, or 21%, in sales of soft tissue repair products, offset by a slight decrease of $46,067, or 2%, in sales of bone fusion products. The increase in net revenue is primarily due to increased sales of soft tissue repair products, including CellerateRX® Surgical Powder and BIASURGE® Advanced Surgical Solution, supported by increased market penetration and geographic expansion, and the Company’s strategy to continue expanding and developing its independent distribution network in both new and existing U.S. markets.

Gross profit for the first quarter of 2026

Share on Social Networks: